Skip to main content

MimiX Biotherapeutics

ApplicationBiel/Bienne, SwitzerlandFounded 2019· One of 381 Application companies tracked by AMPulse

Bioprinting company using Sound Induced Morphogenesis to create skin tissue for wound healing

CEO / Founder
Marc Thurner
Team Size
11-50
Stage
Active
Total Funding
$7.34M
Latest Round
Series A
Key Investors
Venture Kick, Strategic MedTech investors (Asia/Europe)

Technology & Products

Key Products

Sound Induced Morphogenesis (SIM) bioprocessing for tissue manufacturing, with a lead product called FastSkin, a dermal substitute for acute and chronic wound treatment.

Technological Advantage

Proprietary Sound Induced Morphogenesis technology using sound waves to pattern biological tissues

Differentiation

Value Proposition

FastSkin dermal substitute for acute and chronic wounds using revolutionary acoustic cell patterning

How They Differentiate

Unique acoustic cell patterning technology vs conventional bioprinting

Market & Competition

Target Customers

Wound care clinics, hospitals, burn centers, healthcare providers

Industry Verticals

Healthcare, Wound Care, Regenerative Medicine, Bioprinting

Competitors

Volumina Medical, HCS PHARMA, PeptiMatrix

Growth & Milestones

Growth Metrics

Venture Leaders Medtech 2023 participant; Venture Kick Stage 2 winner (2020); FastSkin approaching US FDA clearance

Major Milestones

Founded 2019, Seed funding, Heraeus strategic investment, FDA clearance pathway initiated

Notable Customers

Scientific and clinical research communities, Partners interested in artificial skin applications, Regenerative medicine researchers, Wound care treatment providers

https://mimixbio.com

Why this company matters

MimiX Biotherapeutics occupies a niche at the intersection of bioprinting and regenerative medicine, developing a dermal substitute called FastSkin that relies on acoustic cell patterning rather than conventional extrusion or laser-based bioprinting. The company's Sound Induced Morphogenesis (SIM) technology uses surface acoustic waves to organize cells into functional tissue constructs, a method that could reduce mechanical stress on cells during fabrication.

The core platform is SIM bioprocessing, which employs sound waves to pattern biological materials without the need for a nozzle or scaffold. FastSkin, the lead product, is a dermal substitute designed for acute wounds, such as burns, and chronic wounds like diabetic ulcers. The company is pursuing FDA clearance for FastSkin, positioning it as a potential first-in-class clinical product based on acoustic cell patterning.

Target customers include wound care clinics, hospitals, burn centers, and healthcare providers focused on regenerative medicine. MimiX has secured strategic investment from the Heraeus Group and support from AO Foundation, Venturelab, and Venture Kick. The company was a Venture Leaders Medtech 2023 participant and a Venture Kick Stage 2 winner in 2020.

The primary competitive risk is whether FastSkin can achieve regulatory clearance and clinical adoption faster than established bioprinting alternatives from competitors like Volumina Medical or PeptiMatrix. The acoustic patterning approach offers a differentiation in cell viability and throughput, but the technology must prove scalable and cost-effective in a clinical setting.